Mei Pharma Stock Analysis
MEIP Stock | USD 2.31 0.01 0.43% |
MEI Pharma is undervalued with Real Value of 6.68 and Target Price of 20.0. The main objective of MEI Pharma stock analysis is to determine its intrinsic value, which is an estimate of what MEI Pharma is worth, separate from its market price. There are two main types of MEI Pharma's stock analysis: fundamental analysis and technical analysis.
The MEI Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. MEI Pharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. MEI Stock trading window is adjusted to America/New York timezone.
MEI |
MEI Stock Analysis Notes
About 41.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.71. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MEI Pharma recorded a loss per share of 5.73. The entity last dividend was issued on the 16th of November 2023. The firm had 1:20 split on the 17th of April 2023. MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. To find out more about MEI Pharma contact Justin CPA at 858 369 7100 or learn more at https://meipharma.com.MEI Pharma Investment Alerts
MEI Pharma generated a negative expected return over the last 90 days | |
MEI Pharma has a very high chance of going through financial distress in the upcoming years | |
MEI Pharma currently holds about 153.25 M in cash with (50.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15. | |
Latest headline from finance.yahoo.com: Why PDD Holdings Inc. is a Cheap Internet Stock to Buy According to Hedge Funds |
MEI Pharma Upcoming and Recent Events
8th of February 2024 Upcoming Quarterly Report | View | |
9th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
24th of September 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
30th of June 2023 Last Financial Announcement | View |
MEI Largest EPS Surprises
Earnings surprises can significantly impact MEI Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2022-11-14 | 2022-09-30 | -0.14 | -0.12 | 0.02 | 14 | ||
2021-11-10 | 2021-09-30 | -0.13 | -0.11 | 0.02 | 15 | ||
2017-05-04 | 2017-03-31 | -0.04 | -0.02 | 0.02 | 50 |
MEI Pharma Environmental, Social, and Governance (ESG) Scores
MEI Pharma's ESG score is a quantitative measure that evaluates MEI Pharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of MEI Pharma's operations that may have significant financial implications and affect MEI Pharma's stock price as well as guide investors towards more socially responsible investments.
MEI Pharma Thematic Classifications
In addition to having MEI Pharma stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
![]() | Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
MEI Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Dimensional Fund Advisors, Inc. | 2024-12-31 | 23.4 K | Susquehanna International Group, Llp | 2024-12-31 | 22.6 K | State Street Corp | 2024-12-31 | 17.8 K | Ubs Group Ag | 2024-12-31 | 11.2 K | Virtu Financial Llc | 2024-12-31 | 10.7 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 5.8 K | Newbridge Financial Services Group, Inc. | 2024-12-31 | 2 K | Group One Trading, Lp | 2024-12-31 | 2 K | Tower Research Capital Llc | 2024-12-31 | 1.4 K | Anson Funds Management Lp | 2024-12-31 | 1.1 M | Cable Car Capital Llc | 2024-12-31 | 611.4 K |
MEI Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.32 M.MEI Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.39 | 0.41 | |
Return On Capital Employed | 0.40 | 0.42 | |
Return On Assets | 0.39 | 0.41 | |
Return On Equity | 0.48 | 0.51 |
Management Efficiency
MEI Pharma has return on total asset (ROA) of (0.3068) % which means that it has lost $0.3068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9368) %, meaning that it created substantial loss on money invested by shareholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/14/2025, Return On Tangible Assets is likely to grow to 0.41. Also, Return On Capital Employed is likely to grow to 0.42. At this time, MEI Pharma's Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 03/14/2025, Non Current Liabilities Other is likely to grow to about 26.8 M, while Total Current Liabilities is likely to drop slightly above 8.3 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 5.70 | 5.41 | |
Tangible Book Value Per Share | 5.70 | 5.41 | |
Enterprise Value Over EBITDA | 0.52 | 0.55 | |
Price Book Value Ratio | 0.66 | 0.63 | |
Enterprise Value Multiple | 0.52 | 0.55 | |
Price Fair Value | 0.66 | 0.63 | |
Enterprise Value | 134.9 M | 141.7 M |
The operational strategies employed by MEI Pharma management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Technical Drivers
As of the 14th of March 2025, MEI Pharma secures the mean deviation of 1.65, and Risk Adjusted Performance of (0.08). In connection with fundamental indicators, the technical analysis model lets you check helpful technical drivers of MEI Pharma, as well as the relationship between them.MEI Pharma Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. MEI Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for MEI Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
MEI Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MEI Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on MEI Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MEI Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MEI Pharma Outstanding Bonds
MEI Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MEI Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MEI bonds can be classified according to their maturity, which is the date when MEI Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MTB 465 27 JAN 26 Corp BondUS55279HAV24 | View | |
MTB 47 27 JAN 28 Corp BondUS55279HAW07 | View | |
US55279HAQ39 Corp BondUS55279HAQ39 | View | |
US552704AF51 Corp BondUS552704AF51 | View | |
MUBAUH 37 07 NOV 49 Corp BondUS55276VAK89 | View |
MEI Pharma Predictive Daily Indicators
MEI Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MEI Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 14.13 | |||
Daily Balance Of Power | 0.5 | |||
Rate Of Daily Change | 1.0 | |||
Day Median Price | 2.31 | |||
Day Typical Price | 2.31 | |||
Price Action Indicator | 0.005 | |||
Period Momentum Indicator | 0.01 |
MEI Pharma Corporate Filings
8K | 7th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 12th of February 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 31st of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
20th of December 2024 Other Reports | ViewVerify | |
8K | 25th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 25th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
MEI Pharma Forecast Models
MEI Pharma's time-series forecasting models are one of many MEI Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MEI Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About MEI Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how MEI Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling MEI shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as MEI Pharma. By using and applying MEI Stock analysis, traders can create a robust methodology for identifying MEI entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.25 | 0.26 | |
Operating Profit Margin | 0.20 | 0.21 | |
Net Profit Margin | 0.25 | 0.26 | |
Gross Profit Margin | 0.89 | 0.94 |
Current MEI Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. MEI analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. MEI analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
20.0 | Hold | 2 | Odds |
Most MEI analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand MEI stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of MEI Pharma, talking to its executives and customers, or listening to MEI conference calls.
MEI Stock Analysis Indicators
MEI Pharma stock analysis indicators help investors evaluate how MEI Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading MEI Pharma shares will generate the highest return on investment. By understating and applying MEI Pharma stock analysis, traders can identify MEI Pharma position entry and exit signals to maximize returns.
Begin Period Cash Flow | 16.9 M | |
Total Stockholder Equity | 33 M | |
Property Plant And Equipment Net | 606 K | |
Cash And Short Term Investments | 38.3 M | |
Net Invested Capital | 33 M | |
Shares Float | 4.9 M | |
Cash | 3.7 M | |
200 Day M A | 2.8793 | |
50 Day M A | 2.662 | |
Net Interest Income | 3.3 M | |
Total Current Liabilities | 8.4 M | |
Investments | 49.1 M | |
Dividends Paid | -11.7 M | |
Stock Based Compensation | 2.3 M | |
Common Stock Shares Outstanding | 6.7 M | |
Free Cash Flow | -50.5 M | |
Operating Income | 14.5 M | |
Other Current Assets | 2.4 M | |
Accounts Payable | 3.2 M | |
Net Debt | -3.7 M | |
Depreciation | 383 K | |
Other Operating Expenses | 50.8 M | |
Non Current Assets Total | 606 K | |
Liabilities And Stockholders Equity | 41.4 M | |
Home Category | Domestic |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.